A phase II clinical trial of TTI-622
Latest Information Update: 25 Mar 2021
Price :
$35 *
At a glance
- Drugs Maplirpacept (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Therapeutic Use
- 25 Mar 2021 New trial record
- 18 Mar 2021 According to a Trillium Therapeutics media release, the company expects to initiate this study in 2021.